ArticleBiological trace element research2026
Realgar Transforming Solution as a Novel Arsenic Agent Triggers PINK1/Parkin-Dependent Mitophagy and Apoptosis in the Molm-13 Acute Myeloid Leukemia Cell Line.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAcute myeloid leukemia (AML) remains challenging to treat due to frequent relapse and therapeutic resistance. Mitochondrial stress responses and mitophagy have emerged as critical regulators of leukemic cell fate. Realgar Transforming Solution (RTS) is a highly soluble arsenic preparation bioleached from realgar via Acidithiobacillus ferrooxidans; however, its impact on mitochondrial quality control in AML is poorly defined.
methodsHuman AML cell lines Molm-13 and THP-1, as well as normal human bone marrow stromal cells HS-5, were treated with RTS. Cell viability, apoptosis, oxidative stress, mitochondrial membrane potential, and mitophagy were assessed using CCK-8 assays, Annexin V-FITC/PI flow cytometry, DCFH-DA and JC-1 staining, Western blotting, RT-qPCR, monodansylcadaverine staining, immunofluorescence, and transmission electron microscopy. Mitophagy involvement was evaluated using the Drp1/mitophagy inhibitor Mdivi-1, while mitochondrial ROS contribution was examined using the mitochondrial-targeted antioxidant mitoTEMPO.
resultsAfter 24 h treatment, RTS selectively reduced viability and induced apoptosis in Molm-13 and THP-1 cells, while HS-5 cells were less sensitive. RTS provoked mitochondrial ROS accumulation, MMP loss, Bax/Cyt-c upregulation and Bcl-2 downregulation. Concomitantly, markers of PINK1/Parkin-dependent mitophagy (characterized by increased LC3-II/LC3-I ratio, PINK1/Parkin upregulation, and p62 degradation), increased MDC/TEM autophagic structures, and mitochondrial ultrastructural damage were observed. Pharmacologic inhibition with Mdivi-1 or mitochondrial ROS scavenging with mitoTEMPO significantly attenuated RTS-induced ROS, mitophagy activation, mitochondrial dysfunction and apoptosis.
conclusionIn vitro, RTS induces mitochondrial ROS-dependent activation of PINK1/Parkin-mediated mitophagy that converges on intrinsic mitochondrial apoptosis in AML cells. These data nominate RTS as a mitochondria-targeting candidate for further preclinical evaluation.
Indexed as
Identifiers
41896471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.